The Nursing Clinics of North America 2000: Vol 35 Index

15 Pages·2000·3 MB·English

CUMULATIVE INDEX 2000
Volume 35
PEDIATR IC ADV
RHEUMA I OLOGY, pag 1-299
EVIDENCE-BASED NURSING PRACTICE, pages
INNOVATIVE NURSING PRACTICE, pages 417-582
CLINICAL GENETICS, pages 583-832
ACUTE CARE CARDIOLOGY, pages 833-959
CONTINUING CARE IN ADULT CARDIOLOGY LIVING WITH
4 CARDIAC DIAGNOSIS, pages 961-1060 }
boldface typ
Angiogenesis, gene therapy in, 969
Angioplasty, balloon, 899, 900
Angioscopy, for diagnosis of atherosclero-
sis, 904
\ngiotensin II receptor antagonists, in
management of heart failure, 864
R65
hanisms of, 693, 699 Angiotensin-converting enzyme inhibitors
Alpha-fetoprotein screening in congestive heart failure, 849, 850
Alzheimer, Alois, 688 in management of acute coronary syn
Alzheimer disease, 598 dromes, 883
linical picture of, 688-690 in management of heart failure, 863, 864
Down syndrome and, 690, 691 Antibiotics, in common childhood respira
early-onset, geneticso f, 690-—692 tory illness, judiciousues o f, 87-94
enetics of, 687-694 practical solutions to judicious use of
ite-onset, genetic risk factor for, 69 2 88-92
pathology and treatment of, 690 resistance to, 88
presenilins in, 691, 692 Anticoagulants, in management of heart
stages Of, 059 failure, 868, 869
symptoms of, 689 Antidiuretic hormone, in congestive heart
Americans with Disabilities Act (ADA) failure, 844
747 Anti-inflammatory drugs, nonsteroidal
Amino acid(s), 591 223-244
Amniocentesis, 629, 630 adverse effects of
Analgesia, nonsteroidal anti-inflammatory antiplatelet effects of
drugs for, 231-234 atypical, 227, 228
Anemia, sickle cell, 598, 636 cyclooxygenase hypothesis and, 225-
Anencephaly, 608 drug interactions with, 237 239
Aneuploidy, 611 enantiomeric selectivity of, 228
nterventional therapies for, 899-904
tinal effects of devices used in, 899-901
history and clinical impact « pathophysiology of, 897-899
percutaneous transluminal coronary in
terventions for, YU
fibrillation, role of genetics in, 967
namics of, 6929244 99 S 968
779292
natriuretic factor, in congestive heart
failure, 845, 846
of vantibodies, 187
3] utosomes, 584
igents, In
BSH — YI
n children
sarium swallow with upper gastrointesti
nal series, in children, 20
rlow sign, 96, 97
Bartter syndrome
Base pairs 588, 591
Beta-blockers, in congestive heart
xamination in 850, 851
ive Management ¢ in management of acute
dromes 883
yrp ressin, in « in management of heart failt
Bile acid sequestrants, as lipid lowering
OR6
62, 64, 65
normal development
g
Blount disease, 109
Bone mineral density
Bowlegs, in children
Brachydactyly, 636
myalgia rheumatica Bradykinir 1 congestive heart failure, 847
rheumatoid, 1 steroidal Brain tumor(s), in children, 80, 82, 83
matory drugs for, 23 Breast cancer, genetics in, 663-669
lagement of acute in high-risk women, prevention strate
88? 883 7. 668
geneticso f, 695-705 risk assessment in, 666, 667
disorder, 696 risk factors for, hereditary, 664
ctions and nonhereditary, 664, 665
reening for, for average- and high-ri
pes in women, 665, 666
in children, judicious use
7
of study of, 699
tlons on 700-703
»f, 698, 699
tors for development
ordance studies of alcium channel antagonists, in manage-
102-904 ment of heart failure, 867, 868
iary, directional, 902, 903 ancer(s), 671
tional, 903 colorectal. See Colorectal cancer
iminal extraction catheter hereditary, 605, 671, 672
of breast. See Breast cancer
SCleTOSIS anticoagulation and anti ardiology, interventional, access sites and
platelet regimens in, 909 hemostasis in, 905-909
development of, 984 advances in, 897-912
diagnostic tools for, 904 anticoagulation and antiplatelet regimens
ettect of lipids on, 983-985 in, YOY
CUMULATIVE INDEX 200( 1049
femoral artery access and closure in Clubfoot, 103, 104
S)6-—90R8 Cold, common, in children, judicious use of
future directions in, 909, 9 antimicrobial agents in, 88, 89
nursing care and, 905 Color blindness, 608, 609, 636
radial artery access and closure in Colorectal cancer, 6722 , 673
909 4PC 11307K gene mutation and, 681
ardiomyopathy, hypertrophic, familial familial, 673, 675, 676
657, 658, 962 063 hereditary, 671—685
ardiovascular disease. See also( role of nurse in, 681-684
irtery disease and Heart diseass nonpolyposis, hereditary, 679-681
case management for, outpatient, 991- genetic counseling and testing for, 680
1001 681
gene therapy in, 658, 659 screening and followup for, 681
gene-environment interactions and sporadic, 673
655
omputed tomography (CT) imaging, in
genetics and, 653-661 prenatal testing, 628
risk factors for, genetic influences on, 654 oncussion, in children, management of
73-8]
ase management, 994, 995
by nurse practitioners, 995, 996 oronary artery bypass graft, direct, mini
measures used in, 999, 1000 mally invasive, 913-919
methodsi n, 998, 999 indications for, 914
purposeo f, 997, 998 intraoperative onsiderations in, 914-
research supporting, 997-1001 916
results of, 1000, 1001 nursing considerations in, 919
in cardiovascular disease, 996, 997 outcomes of, 917-919
atheter, central, peripherally inserted. See endoscopic vein harvesting for, 924, 925
Peripherally insert } hybrid procedure of, 921-924
ell division, 596, 597 indications for, 922, 923
hest pain management, evidence-based outcomes of, 923, 924
practice model and, 321-328 radial artery grafts in, 925, 926
evidence-based pl ase | rapid recovery program for, evidence-
evidence-observed phase based practice model in. See Rapid
evidence-supported phase in recovery program for « oronary artery
evidence-triggered phase in bypass graft patients
Children, diabetes m using port access, 919-921
gastroesophageal reflux indications for, 920
genetic testing and screening in, 643-651 intraoperative considerations in, 920
approach to, 646-65 O91
Cholesterol, 980, 981 nursing considerations in, 921
Chorionic villus s ampling, 629 outcomes of, 921
Christmas disease, 636 yronary artery disease. See also Heart
Chromosome(s), 584, 586-596 lisease yronary
disorderso f, 610-614 role of genetics in, 966
mosaicism as, 612-614 surgical treatment of, advances in, 913-
numerical and structural, 610-612 932
sex, 584, 586 oronary syndromes, acute, complications
Chronic disease, self-management of, 506- »f, monitoring for, 891, 892
517 diagnosiso f, 879, 882
background of, 507, 508 management of, new approaches to
immediate objective of, 508 883-890
lessons learned in, 514, 515 new strategies in, 877-895
long-term objectives of, 509 traditional, 882, 883
procedure of, 510, 511 nonpharmacologic interventions for
recommendations for, 515, 516 R93
results of, 511-514 pathophysiology of, 878, 879
setting of study of, 509, 510 psychologic implications of, 892-894
theoretical model of, 509 signs and symptoms of, assessment of,
Cleft lip, 610 890, 891
Cleft palate, 610 spectrum of, 877-881
1050
syndromes | mento f, and vet
nent elevation or
ranch block, 888—89%
egment elevatior
RRA
ixis, examination of n lor wverview of, 482
67_70 ¢ ipproach 481-488
me, 635 learned in 5, 486
| 486
grnNoOsSiISs
nd. 690. 69
tr insparent
ecc dde vices
tatlon
vent of, 1
ry pediatri
mellitus, 61(
d adolescents
or ill child care
f, 1-13
manifestations of
nostic evaluationof , 3, 4
lynamics and specifi
umily educational materials
genetic counseling and, 9
1 development issues
ysiology of, - 2, 3 issues in, 48
list referrals for, 9
6
remento f heart failure, 869 igement ( yt, 37-60
maturational 1 lag and developmental
gestive heart failure, 851 ‘lay as causes of, 42
inm unagemento f heart failure, 866, 867 itional efforts and behavior
Disability insurance, 735 modification in, 48
Disease, chronic. See Chro Ni ii isea nocturnal urine volume as factor in, 43
Diuretics stive heart failure, 848 obstructive sleep apnea and, 44
in management of heart failure, 865, 866 oxybutynin for, 51
sathophysiolog
| l
38-42
enter for Ad
tice, 301-309
yf ) sophe
manometry
geal pH probei n
namics and, 32
il materials fe
ypment
ms for
1cid infusion test
and bronchoscopy in, 22
pathophy
209-221 pharmacok
} ,ositioning strategies fo
surgl il therapy for 5]
symptom ca
treatment of
ultrasound in
ender bias inical trials related to cor
R34. 835
itment of coronary
Familial idenomatous 833, 834
venetk counseling
nical ] tria1 iso f * a J6 6
idenosine deaminase defi
7 766
treatment of, 678 for cancer 66, 767
Familial hypertrophic cardiomy« ypathy importance of gene delivery in
964, 965 in treatment of heart disease, 9¢
Fetal development, criti: new applications of, 768
genetic1 prri nciples, 634-636 new directions in, 767-769
Fetal therapy, 6 31-633 prerequisites for, 758-762
Fetal tissue sampling, 63 delivery as, 760, 761
Fever nonsteroidal anti-inflammatory duration of effect as, 760
drugs for, 230 efficiency as, 759
Fibrates, as lipid lowering agent OR7 evaluation of a clinical protocol as, 76
Fleming, Alexander, 87 molecular nature of the gene as, 758
Foot calcaneovalg s, 98, 100, 101 regulation of the gene as, 758, 759
1052 UMULATIVE INDEX 2006
Gene therapy (cont Glucose-¢ -phosphate dehy drogenase defi-
safety as, 761, 762 ciency, 636
target cell as, 759 Glycoprotein I[b/IIa inhibitors, in manage-
role of health care professional in, 769 ment of acute coronary syndromes,
strategies of, /638, /69 884, 885
Gene transfer, as fetal therapy Growing pains, in childrer
Genes, 584, 586-596 Guanine, 588-—590
Genetic counseling, and genetic testing Guided imagery for coronary artery bypass
615-626 graft patients, evidence-based prac-
1utonomy in, 620-622 tice model for, 417-425
beneficence and, 622 evidence-based phase of, 423
ethical implicationosf , 6 evidence-observed phase of, 420-423
inflicted insight and, 6 4 evidence-supported phase of, 419, 420
informed consent in, 6 ¥.) evidence-tri: ggeraesd pn-a se of, 4‘ 18, 4411 9
nonmaleficence and, 62)2
potential discrimination after, 622, 623
prenatal and pediatric, 623, 624
as a process, 624, 625 Head injuries, mild, in children, 78-80
family history collection and evaluatior Head shape, asymmetric, differential diag-
in, 617, 618 nosiso f, 68, 69
nondirectiveness of, 618, 619 variations of, in infants, 67 er ae?
subspecialties of, 616, 617 Headache(s), migraine, in children, 140
senetic counselors, 615, 616 144
sxenetic Information Nondiscrimination in are, genetics and assumptions re
Health Insurance Act of 1999 41¢9 garding future of, 796, 797
Health insurance, 734-736
senetic testing, for some common genetic
conditions, 636-639 netic discrimination in, 731-756
in pediatric populations, 643-651 and definition of genetic information
potential dilemmas in, 646-650
,enetics, and disturbances in cardiac y test informa-
965-967
and nursing practice, legislative and
u latory con) cerrnr s rel] ated to 723 ) examples of,
basic. 583-598 legislation pertaining to
nursing roles and, 75
clinician’s primer in, 583-614
use of genetic information in, ethical is
genes and chromosomes in, 584, 586-596 736-738
in diagnosis and management of heart
Health Insurance Portability and Account-
dise ase 961-971 ability Act (HIPAA), 748, 749
information resources in, 807-828 Heart defect, congenital, 610
databases as, 820, 821
Heart disease, coronary. See also Coronary
patient support and information orga- artery disease
nizations as, 821, 822
diagnosis and management of, evolving
professional journals as, 823, 824
role of genetics in, 963-973
professional organizations as, 824-826
diagnosis and treatment of, gender bias
Ww eb sites as, 809-820 in, 833, 834
legal issues associated with, 719-729 gene therapy in treatment of, 969-971
nursing programs devoted to, 826-828
in women, 833-839
privacy and confidentiality issues in, his- estrogen and gender-specific hemody-
torical nursing roles and responsi- namics in, 835-837
bilities related to, 720, 721 Heart failure, clinical presentation of, 857
in the managed-care environment 859-862
721-723 congestive, arginine vasopressin in, 844
roles for nurses in relation to, 797, 798 neurohormonal factors in, 841-853
Genome, 584 nonpharmacologic therapies for, 847,
Genotype, 601 848
Genu valgum, in children, 109, 111 renin-angiotensin-aldosterone system
Genu varum, in children, 109, 111 in, 843, 844
Gitelman syndrome, 778 sympathetic nervous system in, 841-
Globus sensation, 18 843
INDEX 2000
definition of, 855, 856 Human Genome Project, 733
diagnosis of, 860 ethical, legal and social implications of
energy, exercise and, 1032 733, 734
management of, angiotensin II receptor Human immunodeficiency virus infection
intagonists, 864, 865 in children, advanced pprraacctt ice nurs
»xtensin-converting enzZzy me inhibi- ing for, 115-124
tors in, 863, 864 central nervous svstem signs of, 120
inticoagulation in, 868, 869 clinical presentation of, 118-121
background and epidemiology of, 855 epidemiology of, 115
beta-blockers in , gastrointestinal system
calcium channel antagoni I ? immunizationasnd , 120
505 ransmission of
irrent tren
let and exercise: ll : ¥ 71 transmissk
treatment of
unter syndrome
untington disea 598, 604, 605
alazine/isosorbide dinitrate, in mar
gement of heart failure, 864
79-78
amilial macrocrania
+-methylglutaryl coenzyme A
luctase, as lipid lowering agent
990)
Hypercholesterolemia, familial, 655, 656
Hypertension 5
control of, variability of, 779
gene therapy for, 779
renetics of 77
hildren
omprehensive care for, 773-793
nursing implicatic oncept ual framework of the clinical
screening for trial of. 782. 783
ttrreeaattmemnetn t ¢o f, 710. , 711 ethic1 al con; siderationisn geneti
femophilia 608, 636 of. 785-788
HepnaD rin, low-. molelce ular-wevieigghhtt. in I m genetic ancillary studieso f, rational.
ywement of acute coronary sy! for, 780, 781
d; rommees RRS genetic-specific research questions and
Hernia(s), inguinal, differential diagnosis hypothesesi n, 781, 782
of, t 1633 protoc ol for genetic studies of, - 784, —7 85
famy ily and pXaattiieenntt eeddiu catitiocn ab} out, + 16a4d recommendations fol1 lowing genetic
in children, 160-164 study of, 788, 789
indications for surgery in, 164 renal impairment in
operative management in, 164 research on, 775, 776
pathophysiology of, 160 study design and interventions in, 783
postoperative care for, 164 784
presentation and management of, 161 target organ complications of, 7
163 monogenetic, 778
Heterozygote, 603 Hypoglycemia, in children with diabetes
Hip dislocation, congenital, 609 mellitus
Hip dysplasia, developmental, in children, Hypotension, monogenetic, 778
95-98 Hypothyroidism, congenital, testing for,
Homozygote, 603 b3a/y
1054 CUMULATIVE INDEX 2006
ichthyosis, 636 at the department of veterans affairs
Immune deficiency, X-linked severe com 572-576
bined, 644-650 ommunicating innovations in, 444, 445
Immune system, cellular, in congestive creating an environment to support and
heart failure, 845 inderpin, 447-449
Immunity, abnormal antigen expression dissemination of, 462-464
ind, 184 applications of approaches to, 466, 467
acquired genetic mutation and, 185 implicationso f, 467, 468
forbidden clone and, 181, 184 methods of, 464—46¢
inadequate suppression and, 184, 185 lirect care providers in health care
loss of self-tolerance and, 180, —18 organizations, 461-470
role of in preventing disease, 178 ‘ luation of, evi1da ence based 1 principles
self versus nonself in, 179, 180 in, 458, 459
Immunization, in children and adolescen i -based pr
evidence ictice anda outcomes
h diabetes mellitus, 1( research in, 454-45
Implantable cardioverter defibrillator, back identifying, 572
imndd oofm , T1a0t1e 8, 1019 l1 inking quali1 ty to, =5- 71
‘i rections of, 110?2 4 nurses as innovators in, n5e7e1 ney
11 pfaamtiileyn,t 1,i0 0222_1 “ ;p romotteim ngc haonfg,e ,d ur4i2n9g- 4r4a1d ical health sys
im t 1 socsoiceiettyy. 1 91223 ity improvement and, 457, 458
indjii cations ff or, 1019 h as a key to promoting and
living with, 1017-1028 meat 453-460
nursing implications of validating and replicating, 445-447
continentia pigment, 605 Innovative organization, creating, 443-451
nfl ammation, role of in preventing disease Insight depression prevention program
7%, 179 329-338
nheritance, autosomal dominant, 60 , model for, 329, 330
iutosomal recessive, 605-607
= evidence-based practicei n
mendelian patterns of, 599, 601-—61( "ae
. evidence-observed phase in
multifactorial, 609 F
2 ; _ evidence-supported phase
X-linked, 607-609 evid.e nce-triggered ph: ase in
nnovative nursing practice, advancing ' , ' :
as pene Insulin replacement, in children
, 569-577 , I. nsurance, terms and 1 concepts in
ind becoming a nurse innovator, 449 ppg es .
c types of 4-736
and 7” BbUr inging innov to the work : II ntoeing, in chil1d ren, 104: -101 6
site, =5 7 Intravenous infusion delivery system, hos
pital-wide, evidence-based practice
and health services research, 557-568
ind transition from clinician to clinical model for, 361-373
administrative support in, 370
researcher, 560-563
ands ej atrrchaenrs,i tio5n6 3, to 5c6l4i nicall] y applied re ceodjn"u vc earetsriiso ino n in,a nd3 170 i mipmlpelmeemnetra tion ion iinn. 37 ]
clinical experience required for, 561 evaluation and selec tion of new intrave
collaboration and, 562, 563 nous pumps in, 207
contribution and opportunity for nurs evaluation and selection of support
ing researchers in, 567, 568 equipment in, 369
examples of, 566, 567 evaluation of, 371
xpected responsibilities in, 564-566 evaluation of current intravenous pumps
in the chronic disease era, 558 in, 368, 369
» managed care environment, 560 evidence-based phase in, 372
opportunity in 557-559 evidj1 e nce-observed phase of, 366-371
quality of care, clinical outcomes, qual evidence-supported phaseo f, 365, 366
ity of life, and cost effectiveness of evidence-triggered phase of, 362 —365
560 intravenous product evaluation fair in
research interest and, 563 369, 370
role conflict and, 561, 562 leadership structures in, 368
ind promoting innovative behaviors methods of, 366-370
569. 570 project management plan in, 367, 368
ATIVE INDEX 2001 1055
purpose of, 366 Marfan syndrome, 605, 636
work groups in, 366, 367 Massage, therapeutic, historical perspective
Introns, 593-594, 596 on, 490
in tertiary and ambulatory care setting
489-497
case studies in, 495, 496
description of, 491-493
evaluation of, 493
yf, 495
Klinefelter syndrome, 612, 635 lessons learned in, 494
Knee replacement, total, anticoagulatic literature review of, 490, 491
therapy after, 407 Mastectomy, prophylactic,fo r women with
mobilization following high risk of breast cancer, 667, 668
-based practice McBurney point, 165, 166
Meiosis, 596, 597
Mendel, ¢ sregor, 583
observed phase o 1 ntal health prevention intervention, In
nce-supported phas f, 407, 4 ght program in, 329-338
evidence-triggered phase of | ‘ttabolism, inborn errors of, 585. See also
lisciplinary approa ( individual nameso f disorders, e.g
lisciplinary tean 4 Phenylketonuria
netic conditions caused by, 610, 611
testing for, 637, 638
Metatarsus adductus
fitosis, 596, 59
Mitral valve prolapse clinic, 1006, 1007
ntol formal and informal education in, 1011
a ye Intolerance
Leukemia(s), mvelo 101 hroni =¢ i as
nutrition, 1012, 1013
iddle syndrome
- . ibout stress reduction techniques, 1013
ife insurance 4 ) amas i
, gaining entry into, 100
imping, in children, 11 : opt
- ; initial evaluatioinn , 1008—1(
Ipid lowering, 956—9A : or
drugs used for, 988-990 newsletter in, 1015 =
gare outcome measures used by, 1015
in p* e9r9s7o n ORwRi th coronary support groups in, .1 014
a hs tl telephone hotline in, 1014, 1015
in person with I Mitral . val:v e prol:a pse syndrome, complica
heart disease
tions of, 1014
ds, definition
treatment of, in nurse-managed outpa
of on atherosclerosis, 983-986
tient mitral valve prolapse clinic,
role of in coronary heart disease, 981-
991 1005-1017
Mobile health and wellness program, for
Lipoprotein(s), 982
rural veterans, 499-505
low density, in pl aque stabilization, 985 backgroundof , 499, 500
986
current status and planned expansion of,
in prevention of endothelial trauma cart
985- markevt5i ng of, .5 01, -5 02
Long OT syndrome, 656, 657
objectives and description of, 500-502
role of genetics in, 968, 969 : 1 '
replication and generalizability potential
Lupus erythematosus, systemic. See $ : ae
temiac lupus erythematosu of for health care systems, 503, 504
strengthso f, 502
Lyon, Mary, 608
Monosomy, 596
Lyonization, 608
Mosaicism, chromosomal, 613, 614
Muscular dystrophy, Duchenne, 598, 608,
609. 636
Macrocrania, familial, 73, 75 Mutation(s), of genes, 598, 600-610
Magnetic resonance imaging, in prenatal acquired, 600, 601
testing, 628 inherited, 598, 600-602
Maple syrup urine disease, 637 somatic, 600
1056 INDEX 200
Myopia, 636 ercise and muscle strengthening in
Myotonic dystrophy, 598 204
hormone replacement ther ipy and 203
joints commonly affected by, 200
medications for, 204, 205
nonsteroidal anti-inflammatory drugs
National Personal Responsibility and Work
for, 23
Opportunity Reconciliation Act of
1996 1 552 nutrition and, 203
N Neonatal te r screening 633, 634 obesity and, 201
‘ seph=rolo gy advanced practice osteoporosis and
overview of
pain control i
Neural tube defects
for, 636, 63 pathogenesis and epidemiolog
rofibromatosis, 605 physical activity and, 202
c examination, pediatric, in pri sarcopenia at na | 1)?<
mary care setting, 61-63 self-efficacy and mood
Neurosurg onditions, pediatric, identi therapeutic interventions
In primary care setting weight loss and wy }
Usteogenesis mmpertecta
ipid lowering agent, 988, 989 Osteomyelitis, in childre
1, as lipid lowering agen Osteoporosis, bisphosph«
bone density and fra
nin in, 195
acute
and Vitamin D
191-193
diagnosis of
Nurs« effectivenesso f ergy x-ray absorptiometry
nontraditional role for, 520, 521
eterans’ compensation and pension ex
aimienat ions using added value to
background of, 519 health history in, 191, 192
st benefits of, 523 individualized approach to, 195, 196
improved outcomeso f, 519-525 intervention for and treatment of, 193
outcomeso f, 521, 522 9
ction and training of 521 nursing management of, 189-197
gnificance of, 520 pathogenesis and epidemiology of, 209
u g educati yn, geneticsi n, 795-805 710
approaches to including, 803, 804 physical examination in, 192
barriers to including, 803 »sychosocial aspects of, 279-286
urriculum considerations and SO0—S03 disability and
necessary knowledge of, 799, 800 education and
xercise and, 283, 284
health perception and, 280
housing modifications for
Oro-faci ital syndrome, 608 interventions for, 282—284
( Irthope aIcs, pe diatric, primary, practi al menopause and, 280
95-113 quality-of-life issues and, 281, 282
Ortolani sign, 96, 97 support groups for, 284
Osteoarthritis, 199-208 selective estrogen receptor modulators
alternative therapies for, 206 in, 194, 195 :
antioxidants and, 201 Otitis media in children, judicious use of
assistive devices and, 204 intimicrobial agents in, 89, 90
classification « f, 200, 201 Outtoeing, 4 in children 106, 109
clinical course of 200
contributing factors in, 201, 202
definitiono f, 199, 200
estrogen and 201 Pacemaker. See Implantabl.
exercise and 213, 214 fibrillator